Gossamer Bio, Inc.
Every calculator, already run for GOSS
Open the full toolkit →You have the numbers on GOSS. Get the argument.
A written report on which of these readings actually decide the outcome for Gossamer Bio, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering GOSSAnalyst Price Target Disagreement for Gossamer Bio, Inc.
Wall Street's bull case implies +2882% from the current price; the bear case implies +109%. A 2774% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for GOSS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and i…
GOSS — frequently asked
Is GOSS a buy right now?
Wall Street's consensus rating on Gossamer Bio, Inc. is Buy across 7 analysts, with a mean price target of $136.48 (+1172% vs. the current $10.73). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is GOSS's next earnings date?
Gossamer Bio, Inc. is next scheduled to report earnings around Nov 4, 2026. A full GOSS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Gossamer Bio, Inc.?
Analysts covering Gossamer Bio, Inc. (GOSS) range from a bear-case target of $22.40 to a bull-case high of $320.00, with a mean consensus target of $136.48 across 5 analysts. The spread of $297.60 (2774% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Gossamer Bio, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Gossamer Bio, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full GOSS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Gossamer Bio, Inc., in minutes. 3 free reports included with every account — no credit card required.